—

Arrowhead Pharmaceuticals Inc(ARWR)— 同类公司组

数据截至2026-10-09 — 评分每个交易日晚间重新计算。分组标准=首先为共同的Closelook指数成分,其次为行业。Closelook研究日记,不构成投资建议。

Arrowhead Pharmaceuticals Inc的Closelook综合评分为45/100,在同类公司组内排名第7位(共7家)——组内评分最高的是Halozyme Therapeutics Inc(74/100)。

名称综合动量质量估值信号距52周高点
ARWR Arrowhead Pharmaceuticals Inc45363412info34.3%
HALO Halozyme Therapeutics Inc74939451ok5.5%
BION.SW BB Biotech AG73589681info13.8%
ONC BeiGene, Ltd.63776232info8%
ARGX.BR Argen-X62537431info21.3%
ARGX argenx NV ADR62507330info23.1%
KRYS Krystal Biotech Inc60638519info13.3%

评分为Closelook全部覆盖范围内的相对读数——方法论见公司评分说明。信号灯来自每日夜间信号看板。

FAQ · from the current data · as of 2026-10-09

Quick answers

Arrowhead Pharmaceuticals Inc在Closelook覆盖范围内的同类公司有哪些?

分组首先基于共同的Closelook指数成分,其次基于行业:Halozyme Therapeutics Inc (HALO)、BB Biotech AG (BION.SW)、BeiGene, Ltd. (ONC)、Argen-X (ARGX.BR)、argenx NV ADR (ARGX)、Krystal Biotech Inc (KRYS)。

ARWR相对同类公司的评分如何?

Arrowhead Pharmaceuticals Inc的综合评分为45/100,组内排名第7位(共7家),截至2026-10-09;组内最高综合评分为Halozyme Therapeutics Inc(74/100)。Closelook评分为研究日记读数,不构成评级或投资建议。

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.